Eteplirsen, an AON that induces DMD exon 51 skipping, received accelerated approval from the Food and Drug Administration (FDA) in the USA based on minimal increases in dystrophin levels in treated DMD patients (Aartsma-Rus and Krieg, 2017). This evidence concerns the gene DMD and Duchenne muscular dystrophy.